Drug Information

Drug (ID: DG00724) and It's Reported Resistant Information

• Name: Dicyclomine
• Synonyms: Dicyclomine; Dicycloverin; Dicycloverine; Bentyl; Bentylol; Diocyl; Wyovin; 77-19-0; Di-syntramine; Dicicloverina; Dicycloverinum; Merbentyl; Procyclomin; Bentomine; Mamiesan; Sawamin; Atumin; Dyspas; 2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate; Oxityl-P; Diocyl hydrochloride; Wyovin hydrochloride; UNII-4KV4X8IF6V; Dicycloverin hydrochloride; [1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; (1,1'-Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; 4KV4X8IF6V; CHEMBL1123; 2-(diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate; 2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate; CHEBI:4514; (Bicyclohexyl)-1-carboxylic acid, 2-(diethylamino)ethyl ester; Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester; NCGC00015368-06; Diethylaminocarbethoxybicyclohexyl hydrochloride; Dicymine; Dicycloverinum [INN-Latin]; Dicicloverina [INN-Spanish]; DSSTox_CID_2926; DSSTox_RID_76790; DSSTox_GSID_22926; Bentyl hydrochloride; Bentylol; Dicyclomine; Dicycloverin; Dicycloverine; Bentylol hydrochloride; Dicycloverine [INN:BAN]; CAS-77-19-0; Dicymine (TN); Dicyclomine [INN]; Dicycloverine (INN); HSDB 3058; NSC-404381; EINECS 201-009-4; Bicyclohexyl-1-carbonsaeure-2'diethylaminoethylester; Byclomine; Kolantyl; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester; Bis(cyclohexyl)carboxylic acid diethylaminoethyl ester hydrochloride; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate; Spectrum_000934; Prestwick0_000048; Prestwick1_000048; Prestwick2_000048; Prestwick3_000048; Spectrum2_000590; Spectrum3_000388; Spectrum4_000509; Spectrum5_000873; Lopac-D-7909; Dicycloverine (Dicyclomine); SCHEMBL3317; Lopac0_000432; BSPBio_000175; BSPBio_002175; GTPL355; KBioGR_001057; KBioSS_001414; DivK1c_000162; SPBio_000440; SPBio_002096; BPBio1_000193; DTXSID1022926; CURUTKGFNZGFSE-UHFFFAOYSA-; KBio1_000162; KBio2_001414; KBio2_003982; KBio2_006550; KBio3_001395; NINDS_000162; HMS3604H12; ZINC1530613; Tox21_113571; 2-diethylaminoethyl 1-cyclohexylcyclohexane-1-carboxylate hydrochloride; BDBM50010101; NSC404381; STL356799; [Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester hydrochloride; AKOS022107181; Tox21_113571_1; CCG-204524; DB00804; MCULE-9110194493; SDCCGSBI-0050417.P005; CAS-67-92-5; IDI1_000162; NCGC00015368-01; NCGC00015368-02; NCGC00015368-03; NCGC00015368-04; NCGC00015368-05; NCGC00015368-07; NCGC00015368-08; NCGC00015368-11; NCGC00015368-17; NCGC00016300-01; NCGC00024386-03; NCGC00024386-04; SBI-0050417.P004; AB00053456; WLN: L6TJ A- AL6TJ AVO2N2&2 &GH; (Bicyclohexyl)-1-carboxylic acid, hydrochloride; C06951; D07820; [1, 2-(diethylamino)ethyl ester, hydrochloride; AB00053456_14; AB00053456_15; L000680; Q2662662; 2-diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate; BRD-K68507560-003-05-5; BRD-K68507560-003-15-4; .beta.-Diethylaminoethyl-1-cyclohexylhexahydrobenzoate hydrochloride; .beta.-Diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate hydrochloride; 104959-55-9
• Indication:
  In total 1 Indication(s)
  Functional bowel syndrome [ICD-11: DD91]; Approved; [1]
• Target: Muscarinic acetylcholine receptor M1 (CHRM1); ACM1_HUMAN; [1]
• Formula: C19H35NO2
• IsoSMILES: CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
• InChI: 1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
• InChIKey: CURUTKGFNZGFSE-UHFFFAOYSA-N
• PubChem CID: 3042
• ChEBI ID: CHEBI:4514
• TTD Drug ID: D07XJM
• VARIDT ID: DR00767
• INTEDE ID: DR2280
• DrugBank ID: DB00804

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-12: Respiratory system diseases

Asthma [ICD-11: CA23]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Cholinergic receptor muscarinic 1 (CHRM1) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Asthma [ICD-11: CA23.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Guinea-pig model; Cavia cutleri
• Experiment for Molecule Alteration: cAMP estimation analysis
• Mechanism Description: Dicyclomine, an antagonist of muscarinic receptors as well as an inhibitor of Ca++ ion influx, exhibited a similar pattern of inhibition with lower EC50 values against CCh when compared with high K+. In isolated guinea pig trachea, TS Oil inhibited carbachol (CCh, 1 M) and K+ (80 mM)-induced contractions in a pattern similar to that of dicyclomine. Methicillin-resistant S. aureus (MRSA) showed a small zone of inhibition as compared to standard strains (22 mm).

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Plasma membrane calcium-transporting ATPase 1 (ATP2B1) [1]

• Molecule Alteration: Function; Inhibition
• Sensitive Disease: Asthma [ICD-11: CA23.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Guinea-pig model; Cavia cutleri
• Experiment for Molecule Alteration: cAMP estimation analysis
• Mechanism Description: Dicyclomine, an antagonist of muscarinic receptors as well as an inhibitor of Ca++ ion influx, exhibited a similar pattern of inhibition with lower EC50 values against CCh when compared with high K+. In isolated guinea pig trachea, TS Oil inhibited carbachol (CCh, 1 M) and K+ (80 mM)-induced contractions in a pattern similar to that of dicyclomine. Methicillin-resistant S. aureus (MRSA) showed a small zone of inhibition as compared to standard strains (22 mm).

References

• Ref 1: Possible Tracheal Relaxant and Antimicrobial Effects of the Essential Oil of Ethiopian Thyme Species (Thymus serrulatus Hochst. ex Benth.): A Multiple Mechanistic Approach .Front Pharmacol. 2021 Apr 5;12:615228. doi: 10.3389/fphar.2021.615228. eCollection 2021. 10.3389/fphar.2021.615228